James N. George , MD

george636439398037709832

George Lynn Cross Research Professor

 

Phone: (405) 271-4222, ext. 48390
Office: The University of Oklahoma Health Sciences Center
801 Northeast 13th Street, Room 335
Post Office Box 26901
Oklahoma City, Oklahoma 73104-5005
Email: James-George@ouhsc.edu

Education and Training:

  • B.A., M.D., The Ohio State University
  • Post-Doctoral Training, Vanderbilt University, Walter Reed Army Institute of Research, University of Rochester

Appointments and Positions:

  • George Lynn Cross Professor, Department of Medicine, 2005-present.
  • Professor, Department of Medicine, University of Oklahoma Health Sciences Center, 1990-present.
  • Assistant, Associate, Professor, Department of Medicine, University of Texas Health Science Center at San Antonio, 1970-1990.

 

National Organizations:

  • American Society of Hematology, President, 2005; Director, Clinical Research Training Institute, 2003, 2004; Editor, ASH Self-Assessment Program, 1st Edition, 2002; Mentor Award Study Section Chair, 2006-2007.
  • National Heart Lung Blood Institute Strategic Planning Working Group, 2006.

Complete List of Publications:

http://profiles.ouhsc.edu/display/74091​

Most Recent 5 Publications:

  • George JN, Nester CM. Syndromes of thrombotic microangiopathy. New Eng J Med 2014; 310 (7): 654-666
  • Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced   thrombotic microangiopathy: a systematic review of published case reports.  Blood 2015; 125 (4): 616-618
  • Han B, Page EE, Stewart LM, Deford CC, Scott JG, Schwartz LH, Perdue JJ, Terrell DR, Vesely SK, George JN.  Depression and cognitive impairment following recovery from acquired thrombotic thrombocytopenic purpura. Amer J Hematol 2015; 90 (8): 709-714
  • Liles NW, Page EE, Liles AL, Vesely SK, Raskob GE, George JN. The Diversity and severity of adverse reactions to quinine: a systematic review. Amer J Hematol 2016; 91 (5): 461-466
  • Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood 2016; 128 (17): 2175-2178

Research Interests:

  • Epidemiology
  • Clinical Course
  • Long-term outcomes of platelet disorders

Current Research Projects:

  • The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry.  This is an inception cohort of all patients with clinically diagnosed TTP or HUS in Oklahoma, excluding the Tulsa region, since January 1, 1999.  The Registry is an ongoing study of the etiology, diagnosis, management, and long-term outcomes of patients with TTP or HUS, excluding only children with typical, Shiga toxin-induced HUS.  Current Registry projects include the association of autoimmune etiologies of TTP with other autoimmune disorders, such as systemic lupus erythematosis and long-term neurocognitive outcomes following recovery from acute episodes of TTP.
  • Immune thrombocytopenic purpura (ITP).  Multiple studies are being conducted to evaluate the safety and effectiveness of new agents to treat patients with ITP.
  • Drug-induced thrombocytopenia.  A continuing Registry has been initiated to document the levels of evidence in all published case reports describing patients with drug-induced thrombocytopenia, to create a comprehensive database on our webite (http://moon.ouhsc.edu/jgeorge) that lists all drugs that have been associated with thrombocytopenia and the level of evidence regarding causality.  Continuing research is comparing our data to data mining of the FDA Adverse Event Reporting System (MedWatch) database, and data on laboratory detection of drug-dependent anti-platelet antibodies.